NDA 213411 · Seagen
Tukysa
Tucatinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 17, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
64
6 Phase 3, 18 recruiting
FAERS reports
7,107
4,642 serious, 729 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY • TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge [see Warnings and Precautions (5.1) ] . • Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue TUKYSA as recommended based on severity of hepatotoxicity [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge. ( 5.1 ) • Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue based on severity. ( 2.3 , 5.1 )
What it is approved for
From the label in effect Oct 14, 2026.
TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. ( 1.1 ) • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.1 Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. 1.2 Unresectable or Metastatic Colorectal Cancer TUKYSA is...
Mechanism: Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro , tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo , tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 7, 2026 Supplement 10 · Efficacy OrphanLetterLabelMedication Guide
- Jan 19, 2023 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Apr 17, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- TUKYSA · TUCATINIB 50MG · TABLET, ORAL · Prescription
- TUKYSA · TUCATINIB 150MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tucatinib" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialPivotal-lookingActive, not recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT04457596 · 1,056 participants · Start Mar 2, 2021 · Primary completion Jan 31, 2028
Drug: Trastuzumab Emtansine; Placebo Administration and 1 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma and 4 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,176 sites in all
Canadian Cancer Trials GroupResearch network
NCT03297606 · 720 participants (planned) · Start Mar 23, 2018 · Primary completion Dec 31, 2026
Drug: Olaparib; Dasatinib and 12 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Edmonton, Canada; Kelowna, Canada; Vancouver, Canada · 10 sites in all
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerPivotal-lookingActive, not recruiting
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT05132582 · 654 participants · Start Mar 7, 2022 · Primary completion Sep 5, 2025
Drug: Tucatinib; Trastuzumab and 3 more · For: HER2 Positive Breast Cancer
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 307 sites in all
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositivePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07413939 · 650 participants (planned) · Start May 21, 2026 · Primary completion May 1, 2029
Drug: RO7771950; Tucatinib and 2 more · For: HER2-positive Breast Cancer
Sites: Huntsville, Alabama; Gilbert, Arizona; Clovis, California · 219 sites in all
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerPivotal-lookingCompleted
Seagen Inc.Pfizer (PFE)
NCT02614794 · 612 participants · Start Jan 28, 2016 · Primary completion Sep 4, 2019
Drug: tucatinib; capecitabine and 2 more · For: HER2 Positive Breast Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Goodyear, Arizona · 176 sites in all
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsPivotal-lookingSuspended
Gruppo Oncologico del Nord-OvestAcademic, hospital or other
NCT05062889 · 477 participants (planned) · Start May 17, 2023 · Primary completion Oct 2027
Drug: 5-Fluorouracil continuous infusion FOLFOXIRI schedule; 5-Fluorouracil bolus FOLFOX schedule and 9 more · For: Stage II Colon Cancer; Stage III Colon Cancer; HER2-positive Colon Cancer and 1 more
Sites: San Giovanni Rotondo, Italy; Tricase, Italy; Arezzo, Italy · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,803
- fatigue980
- nausea941
- vomiting533
- off label use481
- death472
- malignant neoplasm progression455
- palmar-plantar erythrodysaesthesia syndrome418
- product dose omission issue377
- asthenia371
- decreased appetite323
- disease progression306
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 797 |
| 2021 | 1,356 |
| 2022 | 974 |
| 2023 | 931 |
| 2024 | 1,684 |
| 2025 | 765 |
| 2026 | 587 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tukysa (Tucatinib)
2024 spending
$139M
Beneficiaries
1,182
6,463 claims
Per beneficiary
$117,897
$196.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,675,582 |
| 2021 | $81,591,015 |
| 2022 | $91,179,471 |
| 2023 | $102,384,647 |
| 2024 | $139,353,830 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Dieras V, Curigliano G, Martin M, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK, Loi S, Okines A, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N · Breast 2022 · Meta-Analysis
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU, Murthy RK, Abramson V, et al. · JAMA Oncol 2023 · Randomized Controlled Trial, Multicenter Study
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G, Mueller V, Borges V, et al. · Ann Oncol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Okines AFC, Curigliano G, Mizuno N, et al. · Nat Med 2025 · Clinical Trial, Phase II
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.